Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Is there a path for approval of an antiobesity drug: what did the Sibutramine Cardiovascular Outcomes Trial find?

Downey M, Still C, Sharma AM.

Curr Opin Endocrinol Diabetes Obes. 2011 Oct;18(5):321-7. doi: 10.1097/MED.0b013e32834a8726. Review.

PMID:
21878755
2.

Long-term health benefits of appetite suppressants remain unproven.

Paumgartten FJ.

Rev Saude Publica. 2011 Dec;45(6):1192-6.

PMID:
22232806
3.

Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders.

Heal DJ, Gosden J, Smith SL.

Br J Clin Pharmacol. 2009 Dec;68(6):861-74. doi: 10.1111/j.1365-2125.2009.03549.x.

4.

Weight management and current options in pharmacotherapy: orlistat and sibutramine.

Leung WY, Thomas GN, Chan JC, Tomlinson B.

Clin Ther. 2003 Jan;25(1):58-80. Review.

PMID:
12637112
5.

Pharmacotherapy of obesity: currently marketed and upcoming agents.

Bays H, Dujovne C.

Am J Cardiovasc Drugs. 2002;2(4):245-53. Review.

PMID:
14727970
6.

Companies throw their weight behind new antiobesity drugs.

Cahoon L.

Nat Med. 2010 Feb;16(2):136. doi: 10.1038/nm0210-136a. No abstract available.

PMID:
20134442
7.

Pharmacological therapies for obesity.

Kaplan LM.

Gastroenterol Clin North Am. 2005 Mar;34(1):91-104. Review.

PMID:
15823441
8.

New drug policy in childhood obesity.

Molnár D.

Int J Obes (Lond). 2005 Sep;29 Suppl 2:S62-5. Review.

PMID:
16385755
9.

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.

Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.

10.

Lessons learned from independent central review.

Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J.

Eur J Cancer. 2009 Jan;45(2):268-74. doi: 10.1016/j.ejca.2008.10.031.

PMID:
19101138
11.

Food and Drug Administration's Obesity Drug Guidance Document: a short history.

Colman E.

Circulation. 2012 May 1;125(17):2156-64. doi: 10.1161/CIRCULATIONAHA.111.028381. No abstract available.

12.

[Obesity pharmacological treatment].

Pereira Cunill JL, Astorga Jiménez R.

Rev Clin Esp. 2005 Apr;205(4):175-7. Spanish.

PMID:
15860190
13.

New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.

Scheen AJ, Ernest P.

Diabetes Metab. 2002 Dec;28(6 Pt 1):437-45. Review.

14.

Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis.

Neovius M, Johansson K, Rössner S.

Obes Rev. 2008 Sep;9(5):420-7. doi: 10.1111/j.1467-789X.2008.00463.x. Epub 2008 Jan 15. Review.

PMID:
18208467
15.

The discovery and status of sibutramine as an anti-obesity drug.

Luque CA, Rey JA.

Eur J Pharmacol. 2002 Apr 12;440(2-3):119-28. Review.

PMID:
12007530
16.

Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.

Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.

Diabetes Nutr Metab. 2004 Aug;17(4):222-9.

PMID:
15575343
17.

Drug treatment of obesity in the cardiovascular patient.

Charakida M, Tousoulis D, Finer N.

Curr Opin Cardiol. 2013 Sep;28(5):584-91. doi: 10.1097/HCO.0b013e3283642a4c. Review.

PMID:
23928924
18.

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.

Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N, Guvener N.

Diabetes Obes Metab. 2002 Jan;4(1):49-55.

PMID:
11874442
19.

New trends in medicinal chemistry approaches to antiobesity therapy.

Lee J, Song KS, Kang J, Lee SH, Lee J.

Curr Top Med Chem. 2009;9(6):564-96. Review.

PMID:
19689366

Supplemental Content

Support Center